Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/immune-checkpoint-inhibition-in-colorectal-cancer-microsatellite-dQuEngexit
References (94)
-
Brittany Campbell, Nicholas Light, D. Fabrizio, Matthew Zatzman, F. Fuligni, Richard Borja, S. Davidson, M. Edwards, J. Elvin, K. Hodel, Walter Zahurancik, Z. Suo, T. Lipman, K. Wimmer, Christian Kratz, Daniel Bowers, Theodore Laetsch, Gavin Dunn, T. Johanns, M. Grimmer, Ivan Smirnov, Valérie Larouche, David Samuel, A. Bronsema, M. Osborn, D. Stearns, P. Raman, K. Cole, Phillip Storm, M. Yalon, E. Opocher, G. Mason, Gregory Thomas, M. Sabel, B. George, David Ziegler, S. Lindhorst, Vanan Issai, S. Constantini, H. Toledano, R. Elhasid, R. Farah, R. Dvir, Peter Dirks, A. Huang, Melissa Galati, J. Chung, V. Ramaswamy, Meredith Irwin, M. Aronson, C. Durno, Michael Taylor, G. Rechavi, John Maris, E. Bouffet, C. Hawkins, Joseph Costello, M. Meyn, Z. Pursell, D. Malkin, U. Tabori, A. Shlien (2017)
Comprehensive Analysis of Hypermutation in Human CancerCell, 171
-
R. Cohen, O. Buhard, Pascale Cervera, Elisabeth Hain, Sylvie Dumont, A. Bardier, J. Bachet, J. Gornet, D. López-Trabada, R. Kaci, Philippe Bertheau, Florence Renaud, Frédéric Bibeau, Y. Parc, Dewi Vernerey, A. Duval, M. Svrcek, T. André (2017)
Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.European journal of cancer, 86
-
J. Zaretsky, A. García-Díaz, D. Shin, Helena Escuin-Ordinas, Willy Hugo, S. Hu-Lieskovan, D. Torrejon, Gabriel Abril-Rodriguez, Salemiz Sandoval, Lucas Barthly, Justin Saco, B. Moreno, R. Mezzadra, B. Chmielowski, K. Ruchalski, I. Shintaku, P. Sanchez, C. Puig-Saus, Grace Cherry, E. Seja, X. Kong, Jia Pang, B. Berent-Maoz, B. Comin-Anduix, T. Graeber, P. Tumeh, T. Schumacher, R. Lo, A. Ribas (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.The New England journal of medicine, 375 9
-
E. Rayner, I. Gool, C. Palles, S. Kearsey, T. Bosse, I. Tomlinson, D. Church (2016)
A panoply of errors: polymerase proofreading domain mutations in cancerNature Reviews Cancer, 16
-
Chong Sun, R. Mezzadra, T. Schumacher (2018)
Regulation and Function of the PD-L1 Checkpoint.Immunity, 48 3
-
Transforming Growth Factor β Superfamily 27 -
A. Woolston, K. Khan, G. Spain, L. Barber, B. Griffiths, R. Gonzalez-Exposito, Lisa Hornsteiner, M. Punta, Y. Patil, Alice Newey, S. Mansukhani, M. Davies, A. Furness, F. Sclafani, C. Peckitt, Mirta Jiménez, K. Kouvelakis, Romana Ranftl, R. Begum, I. Rana, Janet Thomas, A. Bryant, S. Quezada, A. Wotherspoon, N. Khan, N. Fotiadis, T. Marafioti, T. Powles, S. Lise, F. Calvo, S. Guettler, K. Loga, S. Rao, D. Watkins, N. Starling, I. Chau, A. Sadanandam, D. Cunningham, M. Gerlinger (2018)
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal CancerCancer Cell, 36
-
L. Diaz, A. Marabelle, Tark Kim, R. Geva, E. Cutsem, T. André, P. Ascierto, M. Maio, J. Delord, M. Gottfried, R. Guimbaud, D. Jaeger, E. Élez, T. Yoshino, A. Joe, B. Lam, J. Ding, S. Pruitt, S. Kang, D. Le (2017)
386PEfficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancersAnnals of Oncology, 28
-
S. Kimmel (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints -
A. Patnaik, S. Kang, D. Rasco, K. Papadopoulos, J. Elassaiss-Schaap, M. Beeram, R. Drengler, Cong Chen, L. Smith, G. Espino, K. Gergich, L. Delgado, A. Daud, Jill Lindia, Xiaoyun Li, R. Pierce, J. Yearley, Dianna Wu, O. Laterza, M. Lehnert, R. Iannone, A. Tolcher (2015)
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid TumorsClinical Cancer Research, 21
-
D. McDermott, M. Huseni, M. Atkins, R. Motzer, B. Rini, B. Escudier, L. Fong, R. Joseph, S. Pal, J. Reeves, M. Sznol, J. Hainsworth, W. Rathmell, W. Stadler, Thomas Hutson, M. Gore, A. Ravaud, S. Bracarda, C. Suarez, R. Danielli, V. Gruenwald, T. Choueiri, D. Nickles, S. Jhunjhunwala, E. Piault-Louis, A. Thobhani, J. Qiu, Daniel Chen, P. Hegde, C. Schiff, G. Fine, T. Powles (2018)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaNature Medicine, 24
-
Sung‐Min Ahn, A. Ansari, Jihun Kim, Deokhoon Kim, S. Chun, Jiyun Kim, Tae Kim, I. Park, C. Yu, S. Jang (2016)
The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapyOncotarget, 7
-
S. Fukuoka, H. Hara, N. Takahashi, T. Kojima, A. Kawazoe, M. Asayama, T. Yoshii, D. Kotani, H. Tamura, Y. Mikamoto, A. Sugama, M. Wakabayashi, S. Nomura, A. Sato, Y. Togashi, H. Nishikawa, K. Shitara (2019)
Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603).Journal of Clinical Oncology
-
M Svrcek, O Lascols, R Cohen, A Collura, V Jonchère, J-F Fléjou (2019)
MSI/MMR-deficient tumor diagnosis: which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumorsBull Cancer (Paris)., 106
-
M. Overman, R. McDermott, J. Leach, S. Lonardi, H. Lenz, M. Morse, J. Desai, A. Hill, M. Axelson, R. Moss, Monica Goldberg, Z. Cao, J. Ledeine, G. Maglinte, S. Kopetz, T. André (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.The Lancet. Oncology, 18 9
-
Qian Xiao, Jibo Wu, Wei-jia Wang, Shiyang Chen, Yingxia Zheng, Xiaoqing Yu, Katrina Meeth, M. Sahraei, A. Bothwell, Lieping Chen, M. Bosenberg, Jianfeng Chen, V. Sexl, Le Sun, Lin Li, Wenwen Tang, Dianqing Wu (2018)
DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune cell activationNature medicine, 24
-
Yulian Khagi, A. Goodman, G. Daniels, S. Patel, A. Sacco, J. Randall, L. Bazhenova, R. Kurzrock (2017)
Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based ImmunotherapyClinical Cancer Research, 23
-
Nicolas Llosa, Brandon Luber, Nicholas Siegel, Anas Awan, Teniola Oke, Qingfeng Zhu, Bjarne Bartlett, Laveet Aulakh, E. Thompson, E. Jaffee, J. Durham, C. Sears, D. Le, L. Diaz, D. Pardoll, Hao Wang, F. Housseau, R. Anders (2019)
Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade ImmunotherapyCancer Immunology Research, 7
-
B. Routy, E. Chatelier, L. Derosa, Connie Duong, M. Alou, Romain Daillère, A. Fluckiger, M. Messaoudene, C. Rauber, M. Roberti, M. Fidelle, C. Flament, V. poirier-colame, P. Opolon, C. Klein, Kristina Iribarren, L. Mondragón, N. Jacquelot, B. Qu, Gladys Ferrere, C. Clémenson, L. Mezquita, J. Masip, C. Naltet, S. Brosseau, C. Kaderbhai, C. Richard, H. Rizvi, F. Levenez, N. Galleron, B. Quinquis, N. Pons, B. Ryffel, V. Minard-Colin, P. Gonin, J. Soria, E. Deutsch, Y. Loriot, F. Ghiringhelli, G. Zalcman, F. Goldwasser, B. Escudier, M. Hellmann, A. Eggermont, D. Raoult, L. Albiges, G. Kroemer, L. Zitvogel (2018)
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumorsScience, 359
-
M. Salvador, M. Truelson, C. Mason, B. Souders, H. LaDuca, B. Dougall, M. Black, K. Fulk, J. Profato, Stephanie Gutierrez, K. Jasperson, B. Tippin-Davis, Hsiao-Mei Lu, P. Gray, Swati Shah, E. Chao, Negar Ghahramani, M. Landsverk, C. Gau, Daniel Chen, Melissa Pronold (2019)
Comprehensive Paired Tumor/Germline Testing for Lynch Syndrome: Bringing Resolution to the Diagnostic ProcessJournal of Clinical Oncology, 37
-
M. Overman, S. Lonardi, K. Wong, H. Lenz, F. Gelsomino, M. Aglietta, M. Morse, E. Cutsem, R. McDermott, A. Hill, M. Sawyer, A. Hendlisz, B. Neyns, M. Svrcek, A. Atasoy, Huanyu Zhao, M. Lei, S. Kopetz, T. André (2019)
Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.Journal of Clinical Oncology
-
Z. Stadler, F. Battaglin, S. Middha, J. Hechtman, Christina Tran, A. Cercek, R. Yaeger, N. Segal, A. Varghese, D. Reidy‐Lagunes, N. Kemeny, E. Salo-Mullen, Asad Ashraf, M. Weiser, J. García-Aguilar, M. Robson, K. Offit, M. Arcila, M. Berger, J. Shia, D. Solit, L. Saltz (2016)
Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 18
-
S. Kim, R. Cristescu, A. Bass, Kyoung-Mee Kim, J. Odegaard, Kyung-Mi Kim, Xiao Liu, Xinwei Sher, Hun Jung, Mijin Lee, Sujin Lee, S. Park, Joon-Oh Park, Y. Park, Ho Lim, Hyuk Lee, M. Choi, Amirali Talasaz, P. Kang, Jonathan Cheng, A. Loboda, Jeeyun Lee, W. Kang (2018)
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancerNature Medicine, 24
-
Y. Kwak, Jiwon Koh, Duck-Woo Kim, Sung-Bum Kang, W. Kim, H. Lee (2016)
Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancerOncotarget, 7
-
Response to PD-1 Blockade in Microsatellite 6 -
M. Manzoni, B. Rovati, M. Ronzoni, F. Loupakis, S. Mariucci, V. Ricci, E. Gattoni, L. Salvatore, C. Tinelli, E. Villa, M. Danova (2011)
Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal CancerOncology, 79
-
Jiayi Yu, Xiaowen Wu, Junya Yan, Huan Yu, Longwen Xu, Z. Chi, X. Sheng, L. Si, C. Cui, J. Dai, Meng Ma, Tianxiao Xu, Y. Kong, Jun Guo (2018)
Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patientsJournal of Hematology & Oncology, 11
-
A. Sehdev, H. Cramer, Ashley Ibrahim, A. Younger, B. O'Neil (2016)
Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.Discovery medicine, 21 117
-
F. Pagès, B. Mlecnik, F. Marliot, G. Bindea, F. Ou, C. Bifulco, A. Lugli, I. Zlobec, T. Rau, M. Berger, I. Nagtegaal, Elisa Vink-Börger, A. Hartmann, C. Geppert, J. Kolwelter, S. Merkel, R. Grützmann, M. Eynde, A. Jouret-Mourin, A. Kartheuser, D. Léonard, C. Remue, Julia Wang, P. Bavi, M. Roehrl, P. Ohashi, L. Nguyen, SeongJun Han, Heather MacGregor, S. Hafezi‐Bakhtiari, B. Wouters, G. Masucci, E. Andersson, E. Zavadova, M. Vočka, J. Špaček, L. Petruželka, B. Konopasek, P. Dundr, H. Skálová, K. Němejcová, G. Botti, F. Tatangelo, P. Delrio, G. Ciliberto, M. Maio, L. Laghi, F. Grizzi, T. Fredriksen, Bénédicte Buttard, Mihaela Angelova, A. Vasaturo, Pauline Maby, S. Church, H. Angell, Lucie Lafontaine, Daniela Bruni, Carine Sissy, N. Haicheur, A. Kirilovsky, A. Berger, C. Lagorce, J. Meyers, C. Paustian, Zipei Feng, C. Ballesteros-Merino, J. Dijkstra, C. Water, S. Vliet, N. Knijn, A. Muşină, D. Scripcariu, B. Popivanova, Mingli Xu, T. Fujita, S. Hazama, N. Suzuki, H. Nagano, K. Okuno, T. Torigoe, N. Sato, T. Furuhata, I. Takemasa, K. Itoh, P. Patel, H. Vora, Birva Shah, J. Patel, Kruti Rajvik, S. Pandya, S. Shukla, Yili Wang, Guanjun Zhang, Y. Kawakami, F. Marincola, P. Ascierto, D. Sargent, B. Fox, J. Galon (2018)
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy studyThe Lancet, 391
-
A. Santin, S. Bellone, N. Buza, Jungmin Choi, P. Schwartz, J. Schlessinger, R. Lifton (2016)
Regression of Chemotherapy-Resistant Polymerase ϵ (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with NivolumabClinical Cancer Research, 22
-
P. Laurent-Puig, L. Marisa, M. Ayadi, Y. Blum, R. Balogoun, C. Pilati, K. Malicot, C. Lepage, J. Emile, R. Salazar, D. Aust, A. Duval, J. Selves, D. Guenot, G. Milano, J. Seitz, J. Taieb, V. Boige, A. Reyniès (2018)
Colon cancer molecular subtype intratumoral heterogeneity and its prognostic impact: An extensive molecular analysis of the PETACC-8.Annals of oncology : official journal of the European Society for Medical Oncology, 29 Suppl 8
-
J. Brahmer, S. Tykodi, L. Chow, W. Hwu, S. Topalian, P. Hwu, C. Drake, L. Camacho, J. Kauh, K. Odunsi, H. Pitot, O. Hamid, S. Bhatia, R. Martins, K. Eaton, Shuming Chen, Theresa Salay, S. Alaparthy, J. Grosso, A. Korman, S. Parker, S. Agrawal, S. Goldberg, D. Pardoll, A. Gupta, J. Wigginton (2012)
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.The New England journal of medicine, 366 26
-
J. Jass (2007)
Classification of colorectal cancer based on correlation of clinical, morphological and molecular featuresHistopathology, 50
-
C. Eng, Tae Kim, J. Bendell, G. Argilés, N. Tebbutt, M. Bartolomeo, A. Falcone, M. Fakih, M. Kozloff, N. Segal, A. Sobrero, Yibing Yan, I. Chang, A. Uyei, L. Roberts, F. Ciardiello (2019)
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.The Lancet. Oncology, 20 6
-
D. Le, J. Uram, Hao Wang, Bjarne Bartlett, H. Kemberling, A. Eyring, A. Skora, Brandon Luber, N. Azad, D. Laheru, B. Biedrzycki, R. Donehower, A. Zaheer, G. Fisher, T. Crocenzi, James Lee, Steven Duffy, R. Goldberg, A. Chapelle, M. Koshiji, F. Bhaijee, T. Huebner, R. Hruban, L. Wood, N. Cuka, D. Pardoll, N. Papadopoulos, K. Kinzler, Shibin Zhou, Toby Cornish, J. Taube, R. Anders, J. Eshleman, B. Vogelstein, L. Diaz (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.The New England journal of medicine, 372 26
-
Joana Guerra, C. Pinto, D. Pinto, M. Pinheiro, Romina Silva, Ana Peixoto, P. Rocha, I. Veiga, Catarina Santos, Rui Santos, Verónica Cabreira, P. Lopes, R. Henrique, M. Teixeira (2017)
POLE somatic mutations in advanced colorectal cancerCancer Medicine, 6
-
V. Gopalakrishnan, C. Spencer, L. Nezi, A. Reuben, M. Andrews, T. Karpinets, P. Prieto, D. Vicente, K. Hoffman, S. Wei, Alexandria Cogdill, L. Zhao, C. Hudgens, D. Hutchinson, T. Manzo, M. Macedo, T. Cotechini, T. Kumar, W. Chen, S. Reddy, R. Sloane, J. Galloway-Peña, H. Jiang, P. Chen, E. Shpall, K. Rezvani, A. Alousi, R. Chemaly, S. Shelburne, L. Vence, P. Okhuysen, V. Jensen, A. Swennes, F. McAllister, E. Sanchez, Y. Zhang, E. Chatelier, L. Zitvogel, N. Pons, J. Austin-Breneman, L. Haydu, E. Burton, J. Gardner, E. Sirmans, J. Hu, A. Lazar, T. Tsujikawa, A. Diab, H. Tawbi, I. Glitza, W. Hwu, S. Patel, S. Woodman, R. Amaria, M. Davies, J. Gershenwald, P. Hwu, J. Lee, J. Zhang, L. Coussens, Z. Cooper, P. Futreal, C. Daniel, N. Ajami, J. Petrosino, M. Tetzlaff, P. Sharma, J. Allison, R. Jenq, J. Wargo (2018)
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patientsScience, 359
-
Rajarsi Mandal, R. Samstein, Ken-Wing Lee, J. Havel, Hao Wang, C. Krishna, Erich Sabio, V. Makarov, F. Kuo, P. Blecua, Apoorva Ramaswamy, J. Durham, Bjarne Bartlett, Xiaoxiao Ma, Raghvendra Srivastava, S. Middha, A. Zehir, J. Hechtman, L. Morris, Nils Weinhold, N. Riaz, D. Le, L. Diaz, T. Chan (2019)
Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy responseScience, 364
-
R. Bourdais, B. Rousseau, A. Pujals, H. Boussion, C. Joly, Aude Guillemin, I. Baumgaertner, C. Neuzillet, C. Tournigand (2017)
Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.Critical reviews in oncology/hematology, 113
-
J. Gong, Chongkai Wang, Peter Lee, P. Chu, M. Fakih (2017)
Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE Mutation.Journal of the National Comprehensive Cancer Network : JNCCN, 15 2
-
J. Guinney, R. Dienstmann, Xin Wang, A. Reyniès, A. Schlicker, C. Soneson, L. Marisa, P. Roepman, G. Nyamundanda, P. Angelino, B. Bot, Jeffrey Morris, I. Simon, S. Gerster, E. Fessler, F. Melo, E. Missiaglia, H. Ramay, D. Barras, K. Homicsko, D. Maru, G. Manyam, B. Broom, V. Boige, B. Perez-Villamil, Ted Laderas, R. Salazar, J. Gray, D. Hanahan, J. Tabernero, R. Bernards, S. Friend, P. Laurent-Puig, J. Medema, A. Sadanandam, L. Wessels, M. Delorenzi, S. Kopetz, L. Vermeulen, S. Tejpar (2015)
The Consensus Molecular Subtypes of Colorectal CancerNature medicine, 21
-
D. Fukumura, Jonas Kloepper, Zohreh Amoozgar, D. Duda, R. Jain (2018)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challengesNature Reviews Clinical Oncology, 15
-
M. Gerwing, K. Herrmann, A. Helfen, C. Schliemann, W. Berdel, M. Eisenblätter, M. Wildgruber (2019)
The beginning of the end for conventional RECIST — novel therapies require novel imaging approachesNature Reviews Clinical Oncology, 16
-
R. Samstein, Chung-Han Lee, A. Shoushtari, M. Hellmann, R. Shen, Y. Janjigian, D. Barron, A. Zehir, E. Jordan, A. Omuro, T. Kaley, S. Kendall, R. Motzer, A. Hakimi, M. Voss, P. Russo, J. Rosenberg, G. Iyer, B. Bochner, D. Bajorin, H. Al-Ahmadie, J. Chaft, C. Rudin, Gregory Riely, S. Baxi, A. Ho, R. Wong, D. Pfister, J. Wolchok, C. Barker, P. Gutin, C. Brennan, V. Tabar, I. Mellinghoff, L. Deangelis, C. Ariyan, N. Lee, W. Tap, M. Gounder, S. D’Angelo, L. Saltz, Z. Stadler, H. Scher, J. Baselga, P. Razavi, C. Klebanoff, R. Yaeger, N. Segal, G. Ku, R. DeMatteo, M. Ladanyi, N. Rizvi, M. Berger, N. Riaz, D. Solit, T. Chan, L. Morris (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer typesNature Genetics, 51
-
Alexander Artyomenko, Marcin Sikora, M. Lefterova, V. Raymond, Danielle Gavino, Catalin Barbacioru, C. Artieri, E. Helman, Darya Chudova, R. Lanman, J. Odegaard, J. Willis, M. Fakih, S. Kopetz, Amirali Talasaz (2018)
Microsatellite instability detection by targeted sequencing of cell-free DNA.Annals of oncology : official journal of the European Society for Medical Oncology, 29 Suppl 8
-
Mihaela Angelova, B. Mlecnik, A. Vasaturo, G. Bindea, T. Fredriksen, Lucie Lafontaine, Bénédicte Buttard, Erwan Morgand, Daniela Bruni, A. Jouret-Mourin, C. Hubert, A. Kartheuser, Y. Humblet, M. Ceccarelli, Najeeb Syed, F. Marincola, D. Bedognetti, M. Eynde, J. Galon (2018)
Evolution of Metastases in Space and Time under Immune SelectionCell, 175
-
H. Lenz, E. Cutsem, M. Limón, Ka Wong, Alain Hendlisz, Massimo Aglietta, P. García-Alfonso, B. Neyns, Gabriele Luppi, Dana Cardin, Tomislav Dragovich, Usman Shah, Ajlan Atasoy, R. Postema, Zachary Boyd, J. Ledeine, Michael Overman, S. Lonardi (2018)
Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).Annals of oncology : official journal of the European Society for Medical Oncology, 29 Suppl 8
-
T. Schumacher, R. Schreiber (2015)
Neoantigens in cancer immunotherapyScience, 348
-
L. Marisa, M. Svrcek, A. Collura, E. Becht, P. Cervera, K. Wanherdrick, O. Buhard, A. Goloudina, V. Jonchère, J. Selves, G. Milano, D. Guenot, R. Cohen, C. Colas, P. Laurent-Puig, S. Olschwang, J. Lefèvre, Y. Parc, V. Boige, C. Lepage, T. André, J. Fléjou, V. Derangère, F. Ghiringhelli, A. Reyniès, A. Duval (2018)
The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon TumorsJNCI: Journal of the National Cancer Institute, 110
-
G. Tachon, E. Frouin, L. Karayan‐Tapon, M. Auriault, J. Godet, V. Moulin, Qing Wang, D. Tougeron (2018)
Heterogeneity of mismatch repair defect in colorectal cancer and its implications in clinical practice.European journal of cancer, 95
-
E. Domingo, Luke Freeman-Mills, E. Rayner, M. Glaire, S. Briggs, L. Vermeulen, E. Fessler, J. Medema, Arnoud Boot, H. Morreau, T. Wezel, G. Liefers, R. Lothe, S. Danielsen, A. Sveen, A. Nesbakken, I. Zlobec, A. Lugli, V. Koelzer, M. Berger, S. Castellví-Bel, J. Muñoz, M. Bruyn, H. Nijman, M. Novelli, Kay Lawson, D. Oukrif, E. Frangou, P. Dutton, S. Tejpar, M. Delorenzi, R. Kerr, D. Kerr, I. Tomlinson, D. Church (2016)
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.The lancet. Gastroenterology & hepatology, 1 3
-
C. Pfirschke, Camilla Engblom, S. Rickelt, V. Cortez-Retamozo, Christopher Garris, F. Pucci, T. Yamazaki, V. poirier-colame, Andita Newton, Younes Redouane, Yi-Jang Lin, G. Wojtkiewicz, Y. Iwamoto, M. Mino‐Kenudson, T. Huynh, R. Hynes, G. Freeman, G. Kroemer, L. Zitvogel, R. Weissleder, M. Pittet (2016)
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.Immunity, 44 2
-
D. Le, Tae Kim, E. Cutsem, R. Geva, D. Jäger, H. Hara, M. burge, B. O'Neil, P. Kavan, T. Yoshino, R. Guimbaud, H. Taniguchi, E. Élez, S. Al-Batran, P. Boland, T. Crocenzi, C. Atreya, Yi Cui, T. Dai, P. Marinello, Luis Jr, T. André (2019)
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164Journal of Clinical Oncology, 38
-
A. Sveen, B. Johannessen, Torstein Tengs, S. Danielsen, Ina Eilertsen, Guro Lind, K. Berg, E. Leithe, L. Meza-Zepeda, E. Domingo, O. Myklebost, David Kerr, Ian Tomlinson, A. Nesbakken, R. Skotheim, R. Lothe (2017)
Multilevel genomics of colorectal cancers with microsatellite instability—clinical impact of JAK1 mutations and consensus molecular subtype 1Genome Medicine, 9
-
B. O'Neil, J. Wallmark, D. Lorente, E. Élez, J. Raimbourg, C. Gomez-Roca, S. Ejadi, S. Piha-Paul, M. Stein, A. Razak, K. Dotti, A. Santoro, R. Cohen, M. Gould, S. Saraf, K. Stein, Sae-Won Han (2017)
Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinomaPLoS ONE, 12
-
L. Holubec, J. Polívka, M. Šafanda, M. Karas, V. Liska (2016)
The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment.Anticancer research, 36 9
-
N. Segal, Z. Wainberg, M. Overman, P. Ascierto, H. Arkenau, M. Butler, J. Eder, U. Keilholz, Dong-Wan Kim, D. Cunningham, S. Khleif, L. Doucet, J. Lee, J. Nemunaitis, U. Vaishampayan, J. Weiss, Chen Gao, S. Abdullah, A. Hollebecque (2019)
Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability–high (MSI-H) tumors.Journal of Clinical Oncology
-
L Marisa, M Svrcek, A Collura, E Becht, P Cervera, K Wanherdrick (2018)
The balance between cytotoxic T-cell lymphocytes and immune checkpoint expression in the prognosis of colon tumorsJ Natl Cancer Inst., 110
-
Feng Wang, Qi Zhao, Yingnan Wang, Ying Jin, M. He, Ze-xian Liu, R. Xu (2019)
Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.JAMA oncology
-
CS Grasso, M Giannakis, DK Wells, T Hamada, XJ Mu, M Quist (2018)
Genetic mechanisms of immune evasion in colorectal cancerCancer Discov, 8
-
D. Muzny, M. Bainbridge, K. Chang, H. Dinh, J. Drummond, G. Fowler, C. Kovar, L. Lewis, M. Morgan, I. Newsham, J. Reid, J. Santibanez, E. Shinbrot, L. Treviño, Yuan-qing Wu, Min Wang, P. Gunaratne, L. Donehower, C. Creighton, D. Wheeler, R. Gibbs, M. Lawrence, Douglas Voet, R. Jing, K. Cibulskis, A. Sivachenko, P. Stojanov, A. McKenna, E. Lander, S. Gabriel, L. Ding, R. Fulton, D. Koboldt, T. Wylie, Jason Walker, D. Dooling, L. Fulton, K. Delehaunty, C. Fronick, Ryan Demeter, E. Mardis, R. Wilson, Andy Chu, Hye-Jung Chun, A. Mungall, E. Pleasance, A. Robertson, D. Stoll, M. Balasundaram, I. Birol, Y. Butterfield, E. Chuah, R. Coope, Noreen Dhalla, R. Guin, Carrie Hirst, M. Hirst, R. Holt, Darlene Lee, H. Li, Michael Mayo, Richard Moore, J. Schein, Jared Slobodan, Angela Tam, N. Thiessen, R. Varhol, Thomas Zeng, Yongjun Zhao, Steven Jones, M. Marra, A. Bass, A. Ramos, G. Saksena, A. Cherniack, S. Schumacher, B. Tabak, S. Carter, Nam Pho, Huy Nguyen, R. Onofrio, A. Crenshaw, K. Ardlie, R. Beroukhim, W. Winckler, M. Meyerson, A. Protopopov, A. Hadjipanayis, E. Lee, Ruibin Xi, Lixing Yang, X. Ren, N. Sathiamoorthy, Peng-Chieh Chen, Psalm Haseley, Yonghong Xiao, Semin Lee, J. Seidman, L. Chin, P. Park, R. Kucherlapati, J. Auman, K. Hoadley, Ying Du, M. Wilkerson, Yan Shi, C. Liquori, S. Meng, Ling Li, Yidi Turman, M. Topal, Donghui Tan, S. Waring, Elizabeth Buda, Jesse Walsh, Corbin Jones, P. Mieczkowski, Darshan Singh, Junyuan Wu, Anisha Gulabani, Peter Dolina, T. Bodenheimer, A. Hoyle, J. Simons, Matthew Soloway, Lisle Mose, S. Jefferys, S. Balu, Brian O’Connor, J. Prins, Derek Chiang, D. Hayes, C. Perou, T. Hinoue, D. Weisenberger, D. Maglinte, F. Pan, B. Berman, D. Berg, Hui Shen, T. Triche, S. Baylin, P. Laird, G. Getz, M. Noble, Doug Voat, N. Gehlenborg, D. Dicara, Juinhua Zhang, Hailei Zhang, Chang-Jiun Wu, Spring Liu, S. Shukla, Lihua Zhou, Pei Lin, R. Park, Marc-Danie Nazaire, James Robinson, H. Thorvaldsdóttir, J. Mesirov, V. Thorsson, Sheila Reynolds, Brady Bernard, R. Kreisberg, Jake Lin, L. Iype, Ryan Bressler, Timo Erkkilä, M. Gundapuneni, Yuexin Liu, Adam Norberg, Thomas Robinson, Da Yang, Wei Zhang, I. Shmulevich, J. Ronde, N. Schultz, E. Cerami, G. Ciriello, A. Goldberg, Benjamin Gross, A. Jacobsen, Jianjiong Gao, B. Kaczkowski, Rileen Sinha, B. Aksoy, Yevgeniy Antipin, B. Reva, R. Shen, B. Taylor, M. Ladanyi, C. Sander, R. Akbani, Nianxiang Zhang, B. Broom, Tod Casasent, A. Unruh, Chris Wakefield, S. Hamilton, R. Cason, K. Baggerly, J. Weinstein, D. Haussler, C. Benz, Joshua Stuart, S. Benz, J. Sanborn, Charles Vaske, Jingchun Zhu, C. Szeto, G. Scott, C. Yau, S. Ng, Theodore Goldstein, K. Ellrott, E. Collisson, A. Cozen, D. Zerbino, C. Wilks, Brian Craft, P. Spellman, R. Penny, T. Shelton, M. Hatfield, S. Morris, P. Yena, C. Shelton, M. Sherman, J. Paulauskis, J. Gastier-Foster, Jay Bowen, N. Ramirez, Aaron Black, R. Pyatt, L. Wise, P. White, M. Bertagnolli, Jennifer Brown, T. Chan, Gerald Chu, Christine Czerwinski, F. Denstman, R. Dhir, A. Dörner, C. Fuchs, J. Guillem, M. Iacocca, H. Juhl, Andrew Kaufman, B. Kohl, X. Le, M. Mariano, Elizabeth Medina, M. Meyers, G. Nash, P. Paty, N. Petrelli, B. Rabeno, W. Richards, D. Solit, P. Swanson, L. Temple, J. Tepper, Richard Thorp, E. Vakiani, M. Weiser, J. Willis, G. Witkin, Z. Zeng, M. Zinner, C. Zornig, M. Jensen, R. Sfeir, A. Kahn, A. Chu, Prachi Kothiyal, Zhining Wang, E. Snyder, J. Pontius, T. Pihl, Brenda Ayala, M. Backus, Jessica Walton, J. Whitmore, J. Baboud, D. Berton, M. Nicholls, Deepak Srinivasan, R. Raman, Stanley Girshik, Peter Kigonya, S. Alonso, Rashmi Sanbhadti, S. Barletta, J. Greene, D. Pot, K. Shaw, Laura Dillon, K. Buetow, Tanja Davidsen, John Demchok, G. Eley, M. Ferguson, P. Fielding, C. Schaefer, Margi Sheth, Liming Yang, M. Guyer, B. Ozenberger, Jacqueline Palchik, Jane Peterson, H. Sofia, E. Thomson (2012)
Comprehensive molecular characterization of human colon and rectal cancerNature, 487
-
M. Overman, F. Bergamo, R. McDermott, M. Aglietta, Franklin Chen, F. Gelsomino, M. Wong, M. Morse, E. Cutsem, A. Hendlisz, B. Neyns, R. Moss, Huanyu Zhao, Z. Cao, S. Kamble, S. Kopetz, T. André (2018)
Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.Journal of Clinical Oncology, 36
-
C. Grasso, M. Giannakis, Daniel Wells, Tsuyoshi Hamada, X. Mu, M. Quist, J. Nowak, Reiko Nishihara, Z. Qian, K. Inamura, T. Morikawa, K. Nosho, Gabriel Abril-Rodriguez, C. Connolly, Helena Escuin-Ordinas, M. Geybels, W. Grady, L. Hsu, S. Hu-Lieskovan, J. Huyghe, Yeon Kim, Paige Krystofinski, Mark Leiserson, Dennis Montoya, B. Nadel, M. Pellegrini, C. Pritchard, C. Puig-Saus, Elleanor Quist, Benjamin Raphael, S. Salipante, D. Shin, E. Shinbrot, B. Shirts, S. Shukla, J. Stanford, Wei Sun, J. Tsoi, Alexander Upfill-Brown, D. Wheeler, Catherine Wu, M. Yu, Syed Zaidi, J. Zaretsky, S. Gabriel, E. Lander, L. Garraway, T. Hudson, C. Fuchs, A. Ribas, S. Ogino, U. Peters (2018)
Abstract PR03: Genetic mechanisms of immune evasion in colorectal cancerSystems Immuno-Oncology
-
D. Le, J. Uram, Hao Wang, Bjarne Bartlett, H. Kemberling, A. Eyring, N. Azad, D. Laheru, R. Donehower, T. Crocenzi, R. Goldberg, G. Fisher, James Lee, T. Greten, M. Koshiji, S. Kang, R. Anders, J. Eshleman, B. Vogelstein, L. Diaz (2016)
Programmed death-1 blockade in mismatch repair deficient colorectal cancer.Journal of Clinical Oncology, 34
-
J. Galon, A. Costes, F. Sánchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce-Pagès, M. Tosolini, M. Camus, A. Berger, P. Wind, F. Zinzindohoué, P. Bruneval, P. Cugnenc, Z. Trajanoski, W. Fridman, F. Pagès (2006)
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 313
-
A. Vanderwalde, D. Spetzler, N. Xiao, Z. Gatalica, J. Marshall (2018)
Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patientsCancer Medicine, 7
-
P. Karpiński, J. Rossowska, M. Sąsiadek (2017)
Immunological landscape of consensus clusters in colorectal cancerOncotarget, 8
-
Jianbiao Zhou, S. Toh, Zit-Liang Chan, Jessie Quah, J. Chooi, T. Tan, Phyllis Chong, Q. Zeng, W. Chng (2018)
A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphataseJournal of Hematology & Oncology, 11
-
EX Chen, DJ Jonker, JM Loree, HF Kennecke, S Berry, F Couture (2019)
CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC)J Clin Oncol., 37
-
S. Middha, R. Yaeger, J. Shia, Z. Stadler, Sarah King, Shanna Guercio, Victoriya Paroder, D. Bates, Satshil Rana, L. Diaz, L. Saltz, N. Segal, M. Ladanyi, A. Zehir, J. Hechtman (2019)
Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.JCO precision oncology, 3
-
J Gong, C Wang, PP Lee, P Chu, M Fakih (2017)
Response to PD-1 blockade in microsatellite stable metastatic colorectal cancer harboring a POLE mutationJ Natl Compr Canc Netw, 15
-
Pauline Maby, D. Tougeron, Mohamad Hamieh, B. Mlecnik, H. Kora, G. Bindea, H. Angell, T. Fredriksen, N. Elie, Émilie Fauquembergue, Aurélie Drouet, J. Leprince, J. Benichou, J. Mauillon, F. Pessot, R. Sesboüé, J. Tuech, J. Sabourin, P. Michel, T. Frebourg, J. Galon, J. Latouche (2015)
Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy.Cancer research, 75 17
-
S. Topalian, F. Hodi, J. Brahmer, S. Gettinger, David Smith, David McDermott, J. Powderly, Richard Carvajal, J. Sosman, M. Atkins, P. Leming, D. Spigel, S. Antonia, L. Horn, Charles Drake, D. Pardoll, Lieping Chen, W. Sharfman, Robert Anders, J. Taube, T. McMiller, Haiying Xu, A. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. Kollia, A. Gupta, J. Wigginton, M. Sznol (2012)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.The New England journal of medicine, 366 26
-
B. Jung, Jonas Staudacher, D. Beauchamp (2017)
Transforming Growth Factor β Superfamily Signaling in Development of Colorectal Cancer.Gastroenterology, 152 1
-
Jeffrey Wallin, Johanna Bendell, R. Funke, M. Sznol, K. Korski, Suzanne Jones, G. Hernandez, J. Mier, Xian He, F. Hodi, M. Denker, V. Lévêque, M. Cañamero, Galina Babitski, H. Koeppen, James Ziai, Neeraj Sharma, F. Gaire, Daniel Chen, D. Waterkamp, P. Hegde, David McDermott (2016)
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinomaNature Communications, 7
-
Mihaela Angelova, P. Charoentong, H. Hackl, Maria Fischer, René Snajder, A. Krogsdam, M. Waldner, G. Bindea, B. Mlecnik, J. Galon, Z. Trajanoski (2015)
Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapyGenome Biology, 16
-
S Kopetz, T André, MJ Overman, V Zagonel, S Lonardi, M Aglietta (2018)
Exploratory analysis of Janus kinase 1 (JAK1) loss-of-function (LoF) mutations in patients with DNA mismatch repair-def?cient/microsat- ellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab plus ipilimumab in CheckMate-142Proc Am Assoc Cancer Res., 59
-
M. Bhangoo, P. Boasberg, P. Mehta, J. Elvin, Siraj Ali, Winnie Wu, S. Klempner (2018)
Tumor Mutational Burden Guides Therapy in a Treatment Refractory POLE-Mutant Uterine Carcinosarcoma.The oncologist, 23 5
-
A. Schrock, Ching Ouyang, Ching Ouyang, J. Sandhu, E. Sokol, D. Jin, Jeffrey Ross, Jeffrey Ross, V. Miller, D. Lim, I. Amanam, Joseph Chao, D. Catenacci, May Cho, Fadi Braiteh, S. Klempner, Siraj Ali, M. Fakih (2019)
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.Annals of oncology : official journal of the European Society for Medical Oncology
-
D. Shin, J. Zaretsky, Helena Escuin-Ordinas, A. García-Díaz, S. Hu-Lieskovan, A. Kalbasi, C. Grasso, Willy Hugo, Salemiz Sandoval, D. Torrejon, N. Palaskas, G. Rodriguez, Giulia Parisi, Ariel Azhdam, B. Chmielowski, Grace Cherry, E. Seja, B. Berent-Maoz, I. Shintaku, D. Le, D. Pardoll, Luis Diaz, P. Tumeh, T. Graeber, R. Lo, B. Comin-Anduix, A. Ribas (2017)
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.Cancer discovery, 7 2
-
D. Gandara, S. Paul, M. Kowanetz, E. Schleifman, W. Zou, Yan Li, A. Rittmeyer, L. Fehrenbacher, G. Otto, C. Malboeuf, Daniel Lieber, D. Lipson, J. Silterra, L. Amler, T. Riehl, C. Cummings, P. Hegde, A. Sandler, M. Ballinger, D. Fabrizio, T. Mok, D. Shames (2018)
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabNature Medicine, 24
-
Karen Weintraub (2016)
Take two: Combining immunotherapy with epigenetic drugs to tackle cancerNature Medicine, 22
-
M. Pelster, R. Amaria (2019)
Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trialsTherapeutic Advances in Medical Oncology, 11
-
J. Marin-Acevedo, A. Soyano, B. Dholaria, K. Knutson, Y. Lou (2018)
Cancer immunotherapy beyond immune checkpoint inhibitorsJournal of Hematology & Oncology, 11
-
M. Svrcek, O. Lascols, R. Cohen, A. Collura, V. Jonchère, J. Fléjou, O. Buhard, A. Duval (2019)
MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors.Bulletin du cancer, 106 2
-
J. Brahmer, C. Drake, I. Wollner, J. Powderly, J. Picus, W. Sharfman, E. Stankevich, A. Pons, Theresa Salay, T. McMiller, Marta Gilson, Changyu Wang, M. Selby, J. Taube, R. Anders, Lieping Chen, A. Korman, D. Pardoll, I. Lowy, S. Topalian (2010)
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 19
-
M. Overman, S. Lonardi, K. Wong, H. Lenz, F. Gelsomino, M. Aglietta, M. Morse, E. Cutsem, R. McDermott, A. Hill, M. Sawyer, A. Hendlisz, Bart, Neyns, M. Svrcek, R. Moss, J. Ledeine, Z. Cao, S. Kamble, S. Kopetz, T. André (2018)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 8
-
Daniele Tauriello, Sergio Palomo-Ponce, Diana Stork, A. Berenguer-Llergo, Jordi Badia-Ramentol, M. Iglesias, Marta Sevillano, S. Ibiza, A. Cañellas, Xavier Hernando-Momblona, Daniel Byrom, Joan Matarin, A. Calon, Elisa Rivas, A. Nebreda, A. Riera, Camille Attolini, E. Batlle (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasisNature, 554
-
Dung Le, P. Kavan, Tae Kim, Matthew Burge, Eric Cutsem, H. Hara, Patrick Boland, J. Laethem, R. Geva, H. Taniguchi, T. Crocenzi, M. Sharma, C. Atreya, Luis Diaz, Li Liang, P. Marinello, T. Dai, Bert O'Neil (2018)
KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer.Journal of Clinical Oncology, 36
-
R. Cohen, E. Hain, O. Buhard, Agathe Guilloux, A. Bardier, R. Kaci, P. Bertheau, F. Renaud, F. Bibeau, J. Fléjou, T. André, M. Svrcek, A. Duval (2019)
Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency StatusJAMA Oncology, 5
-
D. Le, D. Le, J. Durham, J. Durham, Kellie Smith, Hao Wang, Bjarne Bartlett, Bjarne Bartlett, Laveet Aulakh, Laveet Aulakh, Steve Lu, Steve Lu, H. Kemberling, C. Wilt, Brandon Luber, F. Wong, F. Wong, N. Azad, A. Rucki, D. Laheru, R. Donehower, A. Zaheer, G. Fisher, T. Crocenzi, James Lee, T. Greten, A. Duffy, K. Ciombor, A. Eyring, B. Lam, A. Joe, S. Kang, M. Holdhoff, L. Danilova, L. Cope, C. Meyer, Shibin Zhou, Shibin Zhou, R. Goldberg, D. Armstrong, K. Bever, A. Fader, J. Taube, F. Housseau, D. Spetzler, N. Xiao, D. Pardoll, N. Papadopoulos, N. Papadopoulos, K. Kinzler, K. Kinzler, J. Eshleman, B. Vogelstein, B. Vogelstein, R. Anders, R. Anders, L. Diaz, L. Diaz (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience, 357
-
E. Becht, A. Reyniès, Nicolas Giraldo, C. Pilati, Bénédicte Buttard, L. Lacroix, J. Selves, C. Sautès-Fridman, P. Laurent-Puig, W. Fridman (2016)
Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision ImmunotherapyClinical Cancer Research, 22
-
Nicolas Llosa, M. Cruise, A. Tam, Elizabeth Wicks, Elizabeth Hechenbleikner, J. Taube, R. Blosser, H. Fan, Hao Wang, Brandon Luber, Ming Zhang, N. Papadopoulos, K. Kinzler, B. Vogelstein, C. Sears, R. Anders, D. Pardoll, F. Housseau (2015)
The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpointsJournal for Immunotherapy of Cancer, 3
-
C. Vanpouille-Box, S. Formenti, S. Demaria (2017)
Toward Precision Radiotherapy for Use with Immune Checkpoint BlockersClinical Cancer Research, 24
- Publisher
- Springer Journals
- Copyright
- Copyright © Springer Nature Switzerland AG 2019
- Subject
- Medicine & Public Health; Oncology; Biomedicine, general
- ISSN
- 1776-2596
- eISSN
- 1776-260X
- DOI
- 10.1007/s11523-019-00690-0
- Publisher site
- See Article on Publisher Site
Abstract
Immune checkpoints inhibitors (ICIs) have been a breakthrough, with unique response and survival patterns compared with chemotherapy for patients with advanced Mismatch Repair-deficient/Microsatellite instable (dMMR/MSI) colorectal cancer, but have shown disappointing results in Mismatch Repair-proficient/Microsatellite stable (pMMR/MSS) colorectal cancer. As up to 50% of patients harboring dMMR/MSI advanced cancers will ultimately progress after PD-1 blockade, biomarkers are needed to predict response/resistance to immunotherapy and to select patients for immunomodulating combination therapies. Patients with pMMR/MSS colorectal cancer present with distinct immune profiles compared to dMMR/MSI tumors, giving evidence of different immune escape mechanisms, which could be overcome through individualized immunotherapeutic strategies. In this review we discuss the latest developments in the field of immunotherapy for dMMR/MSI and pMMR/MSS colorectal cancers, and unresolved questions and considerations concerning the use of ICI therapies in this population. Future immunomodulation strategies based on biomarker selection (tumor mutational burden, Immunoscore®, mutational profile) are discussed.
Journal
Targeted Oncology – Springer Journals
Published: Mar 1, 2020